Genmab Shares Surge 48% on Record‑High Clinical Wins, Upscaling ValuationGenmab’s shares surge 48% after record‑high clinical trial results, prompting major price target upgrades and boosting Danish market sentiment.GENMAB a/S Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 01/11/2026, 05:48 2 minutes to read